Amgen Stock Undervalued by 41.9%: Discounted Cash Flow Model

Amgen's stock price has more than doubled over the past five years, but current valuations suggest it still trades below its intrinsic value. The company's recent clinical wins in oncology and cardiovascular disease have been accompanied by a pullback in share price over the last week and month, leaving investors weighing strong long-term gains against potential undervaluation.

The Discounted Cash Flow model estimates Amgen's intrinsic value at around $673 per share, which is about 41.9% above its recent market price. This gap between price and intrinsic value suggests that the market remains cautious about how much of the company's pipeline will convert into durable cash generation.

Amgen's peers in the biotech industry trade on an average P/E ratio of around 39.2x, while Amgen itself trades at a lower multiple of 24.2x. This discrepancy suggests that investors are willing to pay a premium for large, profitable drug developers like Amgen.